[18F]PI-2620 PET Imaging for Alzheimer's Disease
Trial Summary
What is the purpose of this trial?
This trial tests a brain scan that uses a special substance to detect harmful proteins in people with Alzheimer's disease.
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are receiving aggressive treatment with life-sustaining measures like chemotherapy, you may not be eligible to participate.
What data supports the effectiveness of the drug [18F]PI-2620 for Alzheimer's Disease?
Research shows that [18F]PI-2620 is effective in detecting tau deposits, which are linked to Alzheimer's Disease, using PET imaging. It has been shown to provide clear images that help distinguish between Alzheimer's patients and healthy individuals, and its uptake in the brain correlates with cognitive impairment levels.12345
Is [18F]PI-2620 safe for use in humans?
How is the drug [18F]PI-2620 different from other Alzheimer's treatments?
[18F]PI-2620 is unique because it is a PET imaging tracer specifically designed to bind to tau proteins, which are a hallmark of Alzheimer's disease, allowing for the visualization of tau deposits in the brain. This helps in diagnosing and understanding the progression of Alzheimer's, unlike traditional treatments that focus on symptom management.12347
Research Team
Andrew Stephens, MD, PhD
Principal Investigator
Life Molecular Imaging
Alireza Atri, MD, PhD
Principal Investigator
Banner Health
Eligibility Criteria
This trial is for men and women over 50 with Alzheimer's or terminal conditions like end-stage dementia, who are not on aggressive life-sustaining treatments, have a life expectancy of ≤1 year, can lie in a PET scanner, and consent to brain donation after death. Pregnant women or those without proper contraception are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
PET Imaging
Participants undergo PET imaging with [18F]PI-2620 to detect tau deposition
Follow-up
Participants are monitored for safety and effectiveness after PET imaging
Treatment Details
Interventions
- [18F]PI-2620
[18F]PI-2620 is already approved in United States, European Union for the following indications:
- Detection of tau deposition in Alzheimer's disease
- Detection of tau deposition in Alzheimer's disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Life Molecular Imaging Ltd
Lead Sponsor